Yap B S, Bedikian A Y, Burgess M A, Bodey G P
Am J Clin Oncol. 1982 Dec;5(6):623-5. doi: 10.1097/00000421-198212000-00008.
Twenty-eight patients with disseminated malignant melanoma, who had failed prior therapy, were treated with aziridinylbenzoquinone (AZQ) administered on a 5-day I.V. schedule repeated every 4 weeks. The starting doses were 8 or 6 mg/m2/day x 5 days for good-and-poor-risk patients respectively. There were no complete or partial responses among 23 evaluable patients but four patients had stabilization of disease. The dose-limiting toxicity was thrombocytopenia. Other toxicities included weakness, nausea, vomiting, anorexia, dizziness, abdominal pain, and constipation. AZQ, given on a 5-day schedule, is ineffective in the treatment of patients with metastatic malignant melanoma.
28例既往治疗失败的播散性恶性黑色素瘤患者接受了氮丙啶基苯醌（AZQ）治疗，采用静脉注射，每5天为一个疗程，每4周重复一次。对于预后良好和预后不良的患者，起始剂量分别为8或6mg/m²/天，共5天。23例可评估患者中无完全或部分缓解，但有4例患者病情稳定。剂量限制性毒性为血小板减少。其他毒性包括虚弱、恶心、呕吐、厌食、头晕、腹痛和便秘。按每5天一个疗程给药的AZQ对转移性恶性黑色素瘤患者无效。
